APGE
Apogee Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website apogeetherapeutics.com
- Employees(FY) -
- ISIN US03770N1019
Performance
-4.93%
1W
-0.69%
1M
+40.06%
3M
+199.29%
6M
+80.06%
YTD
+136.98%
1Y
Profile
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Investment Analysis Report: APGE
Overview
APGE is a company operating in the Health Technology sector, specifically in the Biotechnology industry. The company has a market capitalization of $1.34 billion. In this report, we will conduct a comprehensive analysis of APGE's financial statements to evaluate its valuation, financial health, earnings ...
Technical Analysis of APGE 2024-05-10
Overview:
In analyzing the technical indicators for APGE over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions for potential inv...
Recent News & Updates
- 2024-05-15 16:01
- 2024-05-15 04:01
- 2024-05-13 07:42
Apogee Therapeutics' Q1 Net Loss Widens(MT Newswires)
- 2024-05-13 07:00
- 2024-05-13 01:53
- 2024-05-12 19:00
- 2024-05-10 10:13
- 2024-05-08 01:28
- 2024-05-06 08:00
- 2024-05-05 20:00
- 2024-04-16 08:48
- 2024-04-03 07:49
- 2024-03-28 11:01
- 2024-03-27 23:01
- 2024-03-25 07:00
- 2024-03-24 19:00
- 2024-03-24 19:00
- 2024-03-12 16:01
- 2024-03-12 04:01
- 2024-03-07 18:49
- 2024-03-07 05:49
- 2024-03-06 06:02
- 2024-03-05 16:23
- 2024-03-05 16:16
Apogee Catapults 42% After Eczema Drug Blows Expectations Out Of The Water(Investor's Business Daily)
- 2024-03-05 09:53
- 2024-03-05 07:35
IPO Stock Apogee Shifts Higher On Solid Phase 1 Outcome(Investor's Business Daily)
- 2024-03-05 06:10
- 2024-03-05 06:00
Apogee data hint at potential for long-lasting eczema drug(BioPharma Dive)
- 2024-03-05 06:00
- 2024-03-05 03:23
Page 1 of 2
previousnext